| __timestamp | Regeneron Pharmaceuticals, Inc. | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 205018000 | 17293000 |
| Thursday, January 1, 2015 | 392709000 | 26470000 |
| Friday, January 1, 2016 | 299694000 | 28307000 |
| Sunday, January 1, 2017 | 397061000 | 30354000 |
| Monday, January 1, 2018 | 434100000 | 32160000 |
| Tuesday, January 1, 2019 | 782200000 | 37571000 |
| Wednesday, January 1, 2020 | 1119900000 | 39951000 |
| Friday, January 1, 2021 | 2437500000 | 50159000 |
| Saturday, January 1, 2022 | 1560400000 | 54577000 |
| Sunday, January 1, 2023 | 1815800000 | 61940000 |
| Monday, January 1, 2024 | 1970500000 |
Unleashing the power of data
In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This analysis compares the cost of revenue trends for Regeneron Pharmaceuticals, Inc. and Vericel Corporation from 2014 to 2023. Regeneron, a leader in the biotech industry, has seen its cost of revenue grow by approximately 785% over this period, peaking in 2021. This surge reflects its aggressive expansion and increased production capabilities. In contrast, Vericel Corporation, a smaller player, experienced a more modest increase of around 258%, indicating steady growth and strategic scaling. Notably, Regeneron's cost of revenue in 2023 was nearly 30 times that of Vericel, highlighting the disparity in their operational scales. These trends underscore the differing strategies and market positions of these two companies, offering valuable insights for potential investors.
Cost of Revenue Comparison: Bristol-Myers Squibb Company vs Regeneron Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Vericel Corporation
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Regeneron Pharmaceuticals, Inc.
Cost Insights: Breaking Down Zoetis Inc. and Vericel Corporation's Expenses
Cost of Revenue: Key Insights for Regeneron Pharmaceuticals, Inc. and Bio-Techne Corporation
Cost of Revenue Comparison: Regeneron Pharmaceuticals, Inc. vs Exelixis, Inc.
Cost of Revenue: Key Insights for Regeneron Pharmaceuticals, Inc. and Pharming Group N.V.
Analyzing Cost of Revenue: Regeneron Pharmaceuticals, Inc. and Galapagos NV
Cost of Revenue: Key Insights for Regeneron Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.
Cost of Revenue Trends: PTC Therapeutics, Inc. vs Vericel Corporation
Cost of Revenue: Key Insights for Vericel Corporation and Taro Pharmaceutical Industries Ltd.
Cost Insights: Breaking Down Vericel Corporation and MiMedx Group, Inc.'s Expenses